

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 January 2021 (21.01.2021)



(10) International Publication Number
WO 2021/009567 A1

(51) International Patent Classification:

A61P 1/16 (2006.01) *A61P 25/28* (2006.01)
A61P 3/00 (2006.01) *A61P 29/00* (2006.01)
A61P 3/04 (2006.01) *C07C 311/60* (2006.01)
A61P 3/10 (2006.01) *C07D 307/93* (2006.01)
A61P 9/00 (2006.01) *C07D 333/78* (2006.01)
A61P 11/00 (2006.01) *A61K 31/64* (2006.01)
A61P 11/06 (2006.01) *A61K 31/343* (2006.01)
A61P 25/00 (2006.01) *A61K 31/381* (2006.01)
A61P 25/16 (2006.01)

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/IB2020/000668

(22) International Filing Date:

16 July 2020 (16.07.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/875,409 17 July 2019 (17.07.2019) US

(71) Applicant: **ZOMAGEN BIOSCIENCES LTD** [GB/GB];
662 Encinitas Blvd., Suite 250, Encinitas, CA 92024 (US).

(72) Inventors: **MOHAN, Raju**; 662 Encinitas Blvd, Suite 250, Encinitas, CA 92024 (US). **NUSS, John**; 662 Encinitas Blvd, Suite 250, Encinitas, CA 92024 (US). **HARRIS, Jason**; 662 Encinitas Blvd, Suite 250, Encinitas, CA 92024 (US). **YUAN, Shendong**; 662 Encinitas Blvd, Suite 250, Encinitas, CA 92024 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: NLRP3 MODULATORS

(57) Abstract: Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

